Incidence and Risk Factors for Invasive Fungal Infections in Patients Initiating Tumor Necrosis Factor–Alpha Inhibitors for Inflammatory Bowel Disease and Rheumatoid Arthritis
In a commercial claims database analysis, <0.5% of patients with inflammatory bowel disease or rheumatoid arthritis developed an invasive fungal infection (IFI) within 1 year of initiating tumor necrosis factor-alpha therapy. Histoplasmosis was the most common IFI type. Overall IFI incidence varied based on region, underlying conditions, and use of certain immunosuppressive medications.
Authors
- Ian Hennessee (ORCID: https://orcid.org/0000-0001-8807-9566)
- Shari R. Lipner (ORCID: https://orcid.org/0000-0001-5913-9304)
- Kaitlin Benedict (ORCID: https://orcid.org/0000-0003-0458-2493)
- Nathan C. Bahr (ORCID: https://orcid.org/0000-0002-9431-8938)
- Jeremy A.W. Gold (ORCID: https://orcid.org/0000-0002-5054-7616)
Institutions
- Centers for Disease Control and Prevention (US)
- University of Minnesota (US)
- Cornell University (US)
- Epidemic Intelligence Service (US)
- University of Minnesota Medical Center (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1093/cid/ciae444
- Citations
- 11
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 4.28
Funders
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke